Target intelligence / Profile preview

Ribosomal protein

Molecular classification
Ribosomal protein (structural protein), Enzyme (ribosome complex has peptidyl transferase activity), Other (ribosome complex)
01

Overview

Ribosomal protein translation refers to the fundamental cellular process in which the genetic information encoded in messenger RNA (mRNA) is decoded by the ribosome—a large ribonucleoprotein complex composed of ribosomal RNA and ribosomal proteins—to synthesize specific proteins. Proper function of ribosomal proteins ensures accurate translation initiation, elongation, and termination, and is tightly regulated in response to developmental, metabolic, and stress signals. Dysregulation of ribosomal protein translation is implicated in diverse human diseases, including cancer, neurodegenerative disorders, and ribosomopathies such as Diamond-Blackfan anemia. Numerous drugs target this process, especially as antibiotics or in cancer therapeutics, by inhibiting key steps in translation or specific ribosomal subunits. The process itself is not a single molecule but a coordinated function involving the ribosome, mRNA, tRNAs, and translation factors[1][2][3][4][5].

Other names
ribosomeribosomal subunitribosomal proteinprotein synthesis machinery
02

Mechanism of action

Inhibition of translation initiation or elongation (by blocking various functional sites in the ribosome or by targeting ribosomal proteins in prokaryotes) Induction of translation fidelity errors or ribosome stalling

03

Biological functions

Protein synthesisGene expression regulationCell growthCell proliferationRegulation of cell cycle and apoptosis (via translation regulation)
04

Disease associations

Cancer (dysregulated protein synthesis in tumor cells)Infection (antibiotics target bacterial ribosomal proteins)Neurodegenerative disease (translation defects implicated)Hematologic disease (ribosomopathies: e.g. Diamond-Blackfan anemia)Other (developmental disorders)
05

Safety considerations

Off-target toxicity (due to similarities between prokaryotic/eukaryotic ribosomes)Bone marrow suppression (seen with ribosome-inhibiting agents)Developmental toxicityPotential resistance mechanisms (especially for antibiotics)
06

Interacting drugs

Antibiotics (e.g. aminoglycosides, tetracyclines, macrolides: all target bacterial ribosomes)

3 more in the full profile.

07

Biomarkers

Aberrant expression or mutation of ribosomal proteins (e.g. RPS19 in Diamond-Blackfan anemia)Polysome profiling (to measure global translation rates)Phosphorylation state of translation factors (e.g. eIFs, eEF2)

Beyond the preview

Go deeper on Ribosomal protein.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribosomal protein.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call